These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 33284999)

  • 1. Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial.
    Testi AM; Canichella M; Vitale A; Piciocchi A; Guarini A; Starza ID; Cavalli M; De Propris MS; Messina M; Elia L; Moleti ML; Martino B; Luppi M; D'Aloisio M; Candoni A; Conter V; Fazi P; Vignetti M; Chiaretti S; Foà R
    Am J Hematol; 2021 Mar; 96(3):292-301. PubMed ID: 33284999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).
    Rytting ME; Thomas DA; O'Brien SM; Ravandi-Kashani F; Jabbour EJ; Franklin AR; Kadia TM; Pemmaraju N; Daver NG; Ferrajoli A; Garcia-Manero G; Konopleva MY; Cortes JE; Borthakur G; Garris R; Cardenas-Turanzas M; Schroeder K; Jorgensen JL; Kornblau SM; Kantarjian HM
    Cancer; 2014 Dec; 120(23):3660-8. PubMed ID: 25042398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
    Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R
    Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906.
    Bowman WP; Larsen EL; Devidas M; Linda SB; Blach L; Carroll AJ; Carroll WL; Pullen DJ; Shuster J; Willman CL; Winick N; Camitta BM; Hunger SP; Borowitz MJ
    Pediatr Blood Cancer; 2011 Oct; 57(4):569-77. PubMed ID: 21360654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica.
    Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi A; Miniero R; Di Tullio MT; Lo Nigro L; Pession A; Rondelli R; Messina C; Santoro N; Mori PG; De Rossi G; Tamaro P; Silvestri D; Biondi A; Basso G; Masera G
    Haematologica; 1998 Sep; 83(9):791-9. PubMed ID: 9825576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
    Larson RA; Dodge RK; Burns CP; Lee EJ; Stone RM; Schulman P; Duggan D; Davey FR; Sobol RE; Frankel SR
    Blood; 1995 Apr; 85(8):2025-37. PubMed ID: 7718875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.
    Marshall GM; Dalla Pozza L; Sutton R; Ng A; de Groot-Kruseman HA; van der Velden VH; Venn NC; van den Berg H; de Bont ES; Maarten Egeler R; Hoogerbrugge PM; Kaspers GJ; Bierings MB; van der Schoot E; van Dongen J; Law T; Cross S; Mueller H; de Haas V; Haber M; Révész T; Alvaro F; Suppiah R; Norris MD; Pieters R
    Leukemia; 2013 Jul; 27(7):1497-503. PubMed ID: 23407458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Long-term destiny of adolescents and young adults with de novo acute lymphoblastic leukemia treated with a pediatric protocol type].
    López-Hernández MA; Alvarado-Ibarra M; Álvarez-Veral JL; Ortiz-Zepeda M; Guajardo-Leal ML; Cota-Range X
    Gac Med Mex; 2016; 152(5):439-443. PubMed ID: 27792701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.
    Ribera JM; Oriol A; Morgades M; Montesinos P; Sarrà J; González-Campos J; Brunet S; Tormo M; Fernández-Abellán P; Guàrdia R; Bernal MT; Esteve J; Barba P; Moreno MJ; Bermúdez A; Cladera A; Escoda L; García-Boyero R; Del Potro E; Bergua J; Amigo ML; Grande C; Rabuñal MJ; Hernández-Rivas JM; Feliu E
    J Clin Oncol; 2014 May; 32(15):1595-604. PubMed ID: 24752047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Favorable outcome for children and adolescents with T-cell lymphoblastic lymphoma with an intensive ALL-type therapy without local radiotherapy.
    Grenzebach J; Schrappe M; Ludwig WD; Parwaresch R; Zimmermann M; Gadner H; Riehm H; Reiter A;
    Ann Hematol; 2001; 80 Suppl 3():B73-6. PubMed ID: 11757713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia.
    DeAngelo DJ; Stevenson KE; Dahlberg SE; Silverman LB; Couban S; Supko JG; Amrein PC; Ballen KK; Seftel MD; Turner AR; Leber B; Howson-Jan K; Kelly K; Cohen S; Matthews JH; Savoie L; Wadleigh M; Sirulnik LA; Galinsky I; Neuberg DS; Sallan SE; Stone RM
    Leukemia; 2015 Mar; 29(3):526-34. PubMed ID: 25079173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia.
    Brisco J; Hughes E; Neoh SH; Sykes PJ; Bradstock K; Enno A; Szer J; McCaul K; Morley AA
    Blood; 1996 Jun; 87(12):5251-6. PubMed ID: 8652840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of early anthracycline dose-intensity according to expression of Philadelphia chromosome/BCR-ABL rearrangements in B-precursor adult acute lymphoblastic leukemia.
    Bassan R; Rohatiner AZ; Lerede T; Di Bona E; Rambaldi A; Pogliani E; Rossi G; Fabris P; Morandi S; Casula P; Carter M; Lambertenghi-Deliliers G; Lister TA; Barbui T
    Hematol J; 2000; 1(4):226-34. PubMed ID: 11920195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia.
    Panzer-Grümayer ER; Schneider M; Panzer S; Fasching K; Gadner H
    Blood; 2000 Feb; 95(3):790-4. PubMed ID: 10648387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved Outcome of a Pediatric-Inspired Protocol for High-Risk Adolescent and Young Adult Acute Lymphoblastic Leukemia Patients Using Peg-Asparaginase and Escalating Dose of Methotrexate: Tolerability and Outcome.
    Hanbali A; Kotb A; El Fakih R; Alfraih F; Ahmed SO; Shaheen M; Hashmi S; Alhayli S; Alahmari A; Riash MA; Rasheed W; Alzahrani H; Alsharif F; Chaudhri N; Almohareb F; Aljurf M
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):670-677. PubMed ID: 31377206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia.
    Dibenedetto SP; Lo Nigro L; Mayer SP; Rovera G; Schilirò G
    Blood; 1997 Aug; 90(3):1226-32. PubMed ID: 9242556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.
    Möricke A; Zimmermann M; Valsecchi MG; Stanulla M; Biondi A; Mann G; Locatelli F; Cazzaniga G; Niggli F; Aricò M; Bartram CR; Attarbaschi A; Silvestri D; Beier R; Basso G; Ratei R; Kulozik AE; Lo Nigro L; Kremens B; Greiner J; Parasole R; Harbott J; Caruso R; von Stackelberg A; Barisone E; Rössig C; Conter V; Schrappe M
    Blood; 2016 Apr; 127(17):2101-12. PubMed ID: 26888258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Description and prognostic significance of the kinetics of minimal residual disease status in adults with acute lymphoblastic leukemia treated with HyperCVAD.
    Cassaday RD; Stevenson PA; Wood BL; Becker PS; Hendrie PC; Sandmaier BM; Radich JL; Shustov AR
    Am J Hematol; 2018 Aug; 93(4):546-552. PubMed ID: 29318644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia.
    Coustan-Smith E; Sancho J; Hancock ML; Boyett JM; Behm FG; Raimondi SC; Sandlund JT; Rivera GK; Rubnitz JE; Ribeiro RC; Pui CH; Campana D
    Blood; 2000 Oct; 96(8):2691-6. PubMed ID: 11023499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Sancho JM; Ribera JM; Xicoy B; Morgades M; Oriol A; Tormo M; del Potro E; Debén G; Abella E; Bethencourt C; Ortín X; Brunet S; Ortega-Rivas F; Novo A; López R; Hernández-Rivas JM; Sanz MA; Feliu E;
    Eur J Haematol; 2007 Feb; 78(2):102-10. PubMed ID: 17087744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.